Eliquis wins regulatory approvals in U.S., Japan

Editorial Staff | | Cardiovascular Business | Heart Rhythm

The end of the year has proved to be joyous for Bristol-Myers Squibb and Pfizer, whose anticlotting drug apixaban (Eliquis) received back-to-back approvals by the FDA in the U.S. and the Ministry of Health, Labor and Welfare in Japan.

The FDA approved Eliquis on Dec. 28, 2012, with the indication to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (AF). The approval came two days after Japan approved the oral direct factor Xa inhibitor for the same indication, and within months of approval in Canada and the European Union.

The safety and efficacy of Eliquis in treating patients with AF not caused by cardiac valve disease were studied in two clinical trials. ARISTOTLE results showed that apixaban was superior to warfarin in reducing stroke and systemic embolism in AF patients. AVERROES demonstrated that apixaban reduced the risk of stroke or systemic embolism by more than 50 percent in AF patients who were deemed unsuitable to receive vitamin K antagonists without increasing the risk of major bleeding or intracranial hemorrhage.

However, patients in the U.S. with prosthetic heart valves should not take Eliquis nor should patients with AF that is caused by a heart valve problem, according to the product labeling. These patients were not studied in clinical trials. As with other FDA-approved anticlotting drugs, bleeding—including life-threatening and fatal bleeding—is the most serious risk with Eliquis. There is no agent that can reverse the anticoagulant effect of Eliquis.

Eliquis will be dispensed in the U.S. with a patient Medication Guide that provides instructions on its use and drug safety information. Healthcare professionals should counsel patients on signs and symptoms of possible bleeding.

The approval process was drawn out in the U.S. The FDA first assigned it priority review designation in November 2011 with an action date of March 28, 2012. In March, the FDA assigned new goal date of June after the agency requested additional information on data management and verification from the ARISTOTLE trial. Princeton, N.J.-based Bristol-Myers and New York City-based Pfizer reported Sept. 26 that the FDA acknowledged receipt of a New Drug Application resubmission. The FDA then had set a goal date of March 17 for its review.

The application for Eliquis for the prevention of ischemic stroke and systemic embolism was submitted in Japan on Dec. 21, 2011.

Editorial Staff

Related Content

LAAC with Watchman FLX reduces bleeding risks after AFib ablation
Eko Health’s AI platform for digital stethoscopes granted new CPT code
Predicting sudden cardiac death after a heart attack may be impossible—for now
Concomitant ablation surgery during heart operations boosts long-term survival
Johnson & Johnson MedTech gains FDA approval for Varipulse PFA system
Boston Scientific agrees to acquire AFib ablation company

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business
What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."